Citalopram Hydrobromide

Concomitant use increases risk of serotonin syndrome. Citalopram is contraindicated in patients taking linezolid.

Contraindicated due to risk of serotonin syndrome. See CONTRAINDICATIONS and WARNINGS sections.

Concomitant use increases risk of serotonin syndrome. Citalopram is contraindicated in patients taking intravenous methylene blue.

Concomitant use increases risk of serotonin syndrome. Citalopram is contraindicated in patients taking MAOIs.

Concomitant use increases plasma concentrations of pimozide and may increase risk of QT prolongation and ventricular arrhythmias. Citalopram is contraindicated.

Concurrent use may potentiate risk of upper gastrointestinal bleeding due to interference with hemostasis and serotonin reuptake inhibition.

Concomitant use increases risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation and dosage increases.

Concomitant use increases risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation and dosage increases.

Combined administration increases citalopram AUC by 43% and Cmax by 39%, increasing QT prolongation risk. Maximum recommended citalopram dose is 20 mg/day with cimetidine.

Concomitant use increases risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation and dosage increases.

Increases risk of QT prolongation and ventricular arrhythmias. Maximum citalopram dosage is 20 mg daily when used concomitantly.

Concurrent use may potentiate risk of upper gastrointestinal bleeding due to interference with hemostasis and serotonin reuptake inhibition.

Concomitant use increases risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation and dosage increases.

Concomitant use increases risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation and dosage increases.

Concomitant use increases risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation and dosage increases.

Concomitant use increases risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation and dosage increases.

Altered anticoagulant effects and increased bleeding reported. Patients should be carefully monitored when citalopram is initiated or discontinued.

Concomitant use may potentiate risk of bleeding. Inform patients of increased bleeding risk.

Use not recommended in depressed patients taking citalopram, consistent with other psychotropic medications, despite lack of potentiation in clinical trials.

Tricyclic antidepressants increase risk of serotonin syndrome when used concomitantly with citalopram. Monitor for signs and symptoms of serotonin syndrome.

As an SNRI, concomitant use increases serotonin syndrome risk. Monitor for symptoms during initiation and dose increases.

Other SSRIs increase risk of serotonin syndrome when used concomitantly with citalopram. Monitor for signs and symptoms of serotonin syndrome.

Drug Interactions: Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, opioids, amphetamines, or St.

Potent CYP3A4 inhibitor expected to decrease clearance of citalopram.

Potent CYP3A4 inhibitor that might decrease clearance of citalopram, though clinical study showed no significant pharmacokinetic effect.

Potent CYP3A4 inhibitors expected to decrease clearance of citalopram.

Opioids increase risk of serotonin syndrome when used concomitantly with citalopram. Monitor for signs and symptoms of serotonin syndrome.

Potent CYP2C19 inhibitor that might decrease clearance of citalopram.

Concomitant use may potentiate risk of bleeding. Inform patients of increased bleeding risk.

Other SSRIs increase risk of serotonin syndrome when used concomitantly with citalopram. Monitor for signs and symptoms of serotonin syndrome.

Other SSRIs increase risk of serotonin syndrome when used concomitantly with citalopram. Monitor for signs and symptoms of serotonin syndrome.

Triptans increase risk of serotonin syndrome when used concomitantly with citalopram. Monitor for signs and symptoms of serotonin syndrome.

Potential for serotonin syndrome. Caution advised when coadministered with citalopram.

SNRIs increase risk of serotonin syndrome when used concomitantly with citalopram. Monitor for signs and symptoms of serotonin syndrome.

No significant effect on pharmacokinetics of either drug in controlled studies.

Metoprolol - Administration of 40 mg/day citalopram for 22 days resulted in a two-fold increase in the plasma levels of the betaadrenergic blocker metoprolol. Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of citalopram and metoprolol had no clinically significant effects on blood pressure or heart rate.

Triazolam - Combined administration of citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.